ACTU Actuate Therapeutics Inc.

Price (delayed)

$1.37

Market cap

$32.9M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.87

Enterprise value

$28.47M

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways ...

Highlights
ACTU's net income is up by 17% YoY and by 5% from the previous quarter
The EPS rose by 10% since the previous quarter
Actuate Therapeutics's equity has soared by 137% YoY but it has plunged by 74% from the previous quarter
Actuate Therapeutics's quick ratio has soared by 63% YoY but it has decreased by 33% from the previous quarter

Key stats

What are the main financial stats of ACTU

ACTU stock price

How has the Actuate Therapeutics stock price performed over time
Intraday
5.38%
1 week
-18.93%
1 month
29.25%
1 year
-84.09%
YTD
-77.61%
QTD
-10.46%

Financial performance

How have Actuate Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.77M
Net income
-$20.45M
Gross margin
N/A
Net margin
N/A
ACTU's net income is up by 17% YoY and by 5% from the previous quarter
Actuate Therapeutics's operating income has increased by 14% YoY and by 4.9% from the previous quarter

Price vs fundamentals

How does ACTU's price correlate with its fundamentals

Growth

What is Actuate Therapeutics's growth rate over time

Valuation

What is Actuate Therapeutics stock price valuation
P/E
N/A
P/B
33.14
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 10% since the previous quarter
Actuate Therapeutics's equity has soared by 137% YoY but it has plunged by 74% from the previous quarter
ACTU's P/B is 48% above its last 4 quarters average of 21.2

Efficiency

How efficient is Actuate Therapeutics business performance
Actuate Therapeutics's ROA has increased by 37% YoY
Actuate Therapeutics's ROE has increased by 20% from the previous quarter

Dividends

What is ACTU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACTU.

Financial health

How did Actuate Therapeutics financials performed over time
Actuate Therapeutics's total assets is 23% higher than its total liabilities
The current ratio has soared by 71% YoY but it has contracted by 31% from the previous quarter
Actuate Therapeutics's quick ratio has soared by 63% YoY but it has decreased by 33% from the previous quarter
ACTU's debt is 100% lower than its equity
Actuate Therapeutics's equity has soared by 137% YoY but it has plunged by 74% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.